16 November 2015 - According to the findings, there were no statistically significant differences between the treatment groups for the totality of adults with moderate COPD symptoms (severity grade II) and higher severity grades (III-IV) and fewer than two flare-ups (exacerbations) per year. Indications of a minor added benefit could only be derived for women in these COPD groups who inhaled the fixed-dose combination.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/tiotropium/olodaterol-in-copd-disadvantages-in-patients-with-more-severe-disease-advantages-for-some-women.7059.html